# A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

> **NCT04091438** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Idiopathic Hypersomnia

## Interventions

- **DRUG:** TAK-925
- **DRUG:** TAK-925 Placebo

## Key facts

- **NCT ID:** NCT04091438
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-26
- **Primary completion:** 2020-11-19
- **Final completion:** 2020-11-23
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091438, "A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04091438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*